Trial Profile
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Abicipar pegol (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms BAMBOO
- Sponsors Allergan
- 18 Dec 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 10 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 10 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.